Nutrigenomics Market (2026-2036)

The growth of this market is mainly driven by rising consumer and clinical interest in personalised approaches to diet and chronic disease prevention, the integration of genetic information with microbiome, metabolomic, and continuous glucose data into multi-omic nutrition services, the adoption of nutrigenomic testing by dietitians, functional medicine practitioners, and sports organizations as a practice tool, and investment by nutrition and ingredient companies seeking to differentiate products through personalisation. In addition, the growth of personalised supplement subscription models, the use of nutrigenomic research in food and ingredient development, the expansion of academic nutrition genomics research, and growing adoption in Asia-Pacific are further supporting the growth of this market, although growth is tempered by an evidence base that remains stronger in research settings than in consumer applications.

The Nutrigenomics Market, also referred to as the nutritional genomics market, genotype-based personalised nutrition market, or nutrigenetics and nutrigenomics market, comprises the testing services, research products, software, and personalised products through which genetic and related molecular information is used to inform dietary guidance, nutritional products, and research into the interaction between nutrients and the genome. The market includes nutrigenomic and nutrigenetic testing services sold to consumers and through practitioners; research reagents, arrays, and panels used in nutritional genomics research; interpretation software, algorithms, and practitioner platforms that translate genotype and other molecular data into dietary recommendations; and personalised supplement, functional food, and meal planning products formulated or selected on the basis of test results. The market distinguishes nutrigenetics, which examines how genetic variation affects an individual response to nutrients, from nutrigenomics, which examines how nutrients influence gene expression, and in commercial practice most offerings combine both. The market ecosystem extends from testing laboratories, research tool suppliers, software developers, and supplement and food manufacturers to dietitians, functional and integrative medicine practitioners, sports organizations, consumers, academic researchers, and the regulators that govern health claims.

The scientific premise of this market is well established at the level of individual gene-nutrient interactions. Variation in genes affecting caffeine metabolism, lactose digestion, folate metabolism, alcohol processing, and sensitivity to sodium and saturated fat demonstrably influences how individuals respond to specific dietary components, and several of these relationships are robust enough to support dietary advice. The commercial difficulty lies in the distance between these individual findings and a comprehensive personalised diet, because most dietary outcomes are polygenic, heavily influenced by environment and behaviour, and modestly affected by any single variant.

The evidence position is therefore uneven, and credible assessments say so. A review published by the U.K. Food Standards Agency found that personalised nutrition has evolved slowly over more than two decades, that the science is largely convincing in clinical settings but requires significant improvement for consumer use, that approximately 50 genomics-based personalised nutrition providers operate globally with around 15 in the U.K., and that most customers are curiosity buyers making one-off purchases or subscribing for only a few months. This assessment is important commercially rather than merely academically, because it describes a market in which demand is real but retention is poor, and in which the provider base is small and fragmented relative to the attention the category receives.

Multi-omic integration is the principal technical development reshaping the market. Rather than relying on genotype alone, providers increasingly combine genetic variants with gut microbiome composition and activity, metabolomic markers, blood biomarkers, and continuous glucose monitoring, on the reasoning that genotype is fixed while these other measures reflect current state and respond to intervention. Viome Life Sciences, founded in 2016 and employing between 201 and 500 people, raised USD 175 million to accelerate research and development, improve its at-home testing technology, and expand access to its health insights and personalised nutrition recommendations, using technology licensed from Los Alamos National Laboratory to analyse both microbial and human gene expression from a single sample. This approach addresses the central weakness of genotype-only services, which is that a fixed result cannot demonstrate whether an intervention is working.

Practitioner-mediated delivery has proved more durable than direct consumer sales. Dietitians, nutritionists, functional medicine practitioners, and sports organizations use nutrigenomic panels as a structured tool for client assessment and engagement, which places interpretation in professional hands and embeds the test in an ongoing relationship rather than a single purchase. Providers such as Nutrigenomix have built their businesses on this channel, supplying tests through registered practitioners rather than selling directly, and this model attracts less regulatory exposure than consumer health claims made without professional involvement.

The consumer channel has been shaped by the wider consumer genetics market and shares its difficulties. According to database tracking published in March 2026, AncestryDNA was approaching 30 million DNA kits while 23andMe held just under 14 million, down from approximately 15 million in October 2024, indicating both the size of the consumer genotyped population from which nutrigenomic services can draw and the maturity of the consumer genetic testing channel through which many such services have been sold. Nutrition and wellness reports were commonly offered as an add-on to ancestry and health testing, which gave the category reach but associated it with the same problems of one-time purchase, variable scientific rigour, and privacy concern that affected consumer genomics generally.

Regulation of claims is the defining constraint on how this market can be commercialised. Enforcement precedent in this market was established when the U.S. Federal Trade Commission settled with a marketer of genetically customized nutritional supplements over claims that the company could not substantiate, establishing that nutrigenomic product claims are subject to the same substantiation requirements as other health claims and that genetic personalisation does not exempt a supplement claim from the need for competent and reliable scientific evidence. The same review concluded that advice based on DNA data sits at the edge of regulatory remit, that DNA-based claims require a stronger regulatory position, that test results should come from certified laboratories meeting national validation standards, and that the algorithms generating personalised advice are frequently built on the knowledge of individual company scientists and should be open to external validation, recommending a harmonised framework covering test validity, algorithm standards, data ownership, and privacy. The practical consequence is that providers must either confine themselves to claims supported by robust evidence, which limits the scope of what they can offer, or route advice through a qualified practitioner, which limits scale but transfers interpretive responsibility.

The market includes practitioner-channel testing providers such as Nutrigenomix and GX Sciences, multi-omic consumer providers including Viome and Zoe, genetics-led wellness providers such as DNAfit within Prenetics and GenoPalate, personalised supplement companies, and nutrition and ingredient companies including dsm-firmenich that use nutrigenomic research in product development and offer personalisation platforms to brands. Research tool suppliers including Thermo Fisher Scientific, Illumina, QIAGEN, and Agilent Technologies supply the arrays, panels, and reagents used in nutritional genomics research. Participants compete on the scientific defensibility of their panels and algorithms, the credibility of their claims, practitioner relationships, integration of multi-omic data, subscription retention, and the quality of the dietary guidance delivered.

At the same time, the market faces substantial challenges, including an evidence base that supports individual gene-nutrient relationships far better than comprehensive personalised diets, poor consumer retention characteristic of curiosity purchases, the absence of harmonised standards for algorithm validation, regulatory limits on claims, scepticism among dietitians and clinical nutrition bodies about the clinical utility of genotype-based advice, and competition from phenotype-based personalisation using glucose or microbiome data that does not require genetic testing at all. As a result, participants that combine defensible science, practitioner distribution, multi-omic measurement that can demonstrate response, and recurring-revenue products are expected to capture the largest share of growth over the forecast period.